iQIYI

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Chinese cities are subsidizing AI filmmakers as falling production costs drive an explosion of artificial-intelligence-generated dramas, videos and feature-film experiments. Representative image.

Can China turn cheap AI-generated video into its next globally dominant industry?

China is applying subsidies, computing support and industrial-cluster policies to AI-generated film and video, driving production costs sharply lower while raising concerns about oversupply, copyright and creative-industry disruption.

byVenkatesh

September 25, 2026

iQIYI Begins Construction of iQIYI LAND, Its First Theme Park, Expanding Offline Entertainment Offerings

iQIYI expands beyond streaming with iQIYI LAND, its first immersive theme park in Yangzhou

iQIYI, China’s leading online entertainment platform, is making a major leap into offline entertainment experiences with the development…

byPallavi Madhiraju

March 16, 2025

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Can China turn cheap AI-generated video into its next globally dominant industry?

iQIYI expands beyond streaming with iQIYI LAND, its first immersive theme park in Yangzhou

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?